TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04602923

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: OPD-Scan
Description: Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
Study: NCT03830320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Study: NCT04602923

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: OPD-Scan
Description: Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: OPD-Scan
Description: Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: Pentacam
Description: Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: Pentacam
Description: Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
Study: NCT03830320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner
Study: NCT04602923

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: Pentacam
Description: Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
Study: NCT00514462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: wavelength at 830nm, 9.7J/cm2 for 10 min
Study: NCT00444067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Sealant
Description: Spinal Sealant System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT02461082

Intervention type: DEVICE
Group type: OTHER
Intervention: Expiratory muscle strength training (EMST)
Description: The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).

Intervention type: DEVICE
Group type: OTHER
Intervention: Expiratory muscle strength training (EMST)
Description: The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).

Intervention type: DEVICE
Group type: OTHER
Intervention: Expiratory muscle strength training (EMST)
Description: The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).

Intervention type: DEVICE
Group type: OTHER
Intervention: Expiratory muscle strength training (EMST)
Description: The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
Study: NCT02626390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequent instructions/feedback and an Internal Focus of Attention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal instructions/feedback and an External Focus of Attention
Study: NCT06149377

Intervention type: PROCEDURE
Intervention: Test cohort
Study: NCT01438177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Study: NCT03830320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner
Study: NCT04546347

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)
Description: Dose of \[14C\]AZD9833 Solution for Infusion
Study: NCT01143194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of placebo twice a day
Study: NCT02839694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine (DAC)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine (DAC)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine (DAC)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrouridine (THU)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study: NCT03830320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner
Study: NCT02839694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 400 mg orally twice a day every day for while on DAC-THU therapy
Study: NCT04506203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air test
Description: Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
Study: NCT03989323

Intervention type: OTHER
Intervention: Estimation of the incidence of the irAE
Description: Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
Study: NCT04123613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
Study: NCT04546347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet A Dose 1
Description: Dose 1 AZD9833 film-coated tablet A Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 Oral Solution
Description: AZD9833 Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet B Dose 1
Description: AZD9833 film-coated tablet B Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet A Dose 2
Description: Dose 1 of AZD9833 film-coated tablet A Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet B Dose 2
Description: Dose 1 of film-coated tablet B Dose 2
Study: NCT04508842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-Dual-STAR-T
Description: Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
Study: NCT00109395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam CI
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study: NCT02976974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: * Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension
Study: NCT00851799

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC

Intervention type: DRUG
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV

Intervention type: DRUG
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV

Intervention type: DRUG
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV

Intervention type: DRUG
Intervention: Atazanavir
Description: 300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV

Intervention type: DRUG
Intervention: Raltegravir
Description: 400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL

Intervention type: DRUG
Intervention: Darunavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV
Study: NCT05948202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Treatment
Description: Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
Study: NCT02196272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led reminder program through email
Description: Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form.
Study: NCT04574804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training program in weight management for osteoarthritis
Description: An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention.
Study: NCT00451867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Study: NCT02565303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
Study: NCT00364351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet
Study: NCT00451867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycofenolate Mofetil (MMF)
Description: 2000 mg per day divided into 2 equal doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01749579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
Study: NCT03830320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
Study: NCT02338999

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01933100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
Study: NCT01945372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG NeuroFeedback

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EEG NeuroFeedback
Study: NCT02402270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuLYTELY® (PEG 3350)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP-019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP-019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP-019
Study: NCT00364351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: oral dose
Study: NCT03513835

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic screenings tests
Description: Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic screenings tests
Description: Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
Study: NCT02402270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep® (PEG 3350)
Study: NCT02976272

Intervention type: OTHER
Intervention: bortezomib
Study: NCT00694304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 2.5, 5, or 10 mg/day; tablets; orally
Study: NCT02027753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02995408

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program for Parents of Children with ASD
Study: NCT00756951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: 0.02 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: 0.10 mg/kg
Study: NCT03737110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rilonacept
Description: Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
Study: NCT02257203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Beverage Education
Description: Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Education
Description: Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
Study: NCT03737110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injections once weekly
Study: NCT01307345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for abstinence
Description: For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
Study: NCT00639418

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
Study: NCT03288363

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
Study: NCT03843801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endomina
Description: The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.